Meeting
2019 ASCO Annual Meeting
End-of-life care and immune checkpoint inhibitors.
Authors
Hazel O'Sullivan
Cork University Hospital, Cork, Ireland
Hazel O'Sullivan , Dearbhaile Collins , Deirdre O'Mahony , Derek Power , Richard Bambury , Seamus O'Reilly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
End-of-Life Care
Citation
J Clin Oncol 37, 2019 (suppl; abstr 11531)
DOI
10.1200/JCO.2019.37.15_suppl.11531
Abstract #
11531
Poster Bd #
223
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Quality Care Symposium
The Inpatient Immunotherapy Outcomes study: A multicenter retrospective study of patients treated with immune checkpoint inhibitors in the inpatient setting.
First Author: Fauzia Riaz
Poster
2020 ASCO Virtual Scientific Program
INMUNOSUN-SOGUG trial: A prospective phase II study to assess the efficacy and safety of sunitinib as second-line (2L) treatment in patients (pts) with metastatic renal cell cancer (RCC) who received immunotherapy-based combination upfront.
First Author: Enrique Grande
Poster
2018 ASCO Quality Care Symposium
A data driven approach to immunotherapy toxicity management.
First Author: Sadiqa Mahmood
Poster
2022 ASCO Annual Meeting
Comparing rate of immunotherapy treatment change due to toxicity by gender.
First Author: Kevin Joseph Chua